Beckman Coulter Says Q2 Revenues Miss Expectations
 
Revenues dropped in the second quarter for Beckman Coulter as sales in the Far East and in life science markets fell below expectations, the company said this week.
 
Beckman reported revenues of $616.3 million for the quarter, short of the $620 million to $645 million forecast by the company on May 3. During the second quarter of 2005, Beckman Coulter posted revenues of $618.8 million.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.